Literature DB >> 22552800

Reproducibility of the nicotine metabolite ratio in cigarette smokers.

Gideon St Helen1, Maria Novalen, Daniel F Heitjan, Delia Dempsey, Peyton Jacob, Adel Aziziyeh, Victoria C Wing, Tony P George, Rachel F Tyndale, Neal L Benowitz.   

Abstract

BACKGROUND: The nicotine metabolite ratio (NMR or 3-hydroxycotinine/cotinine) has been used to phenotype CYP2A6-mediated nicotine metabolism. Our objectives were to analyze (i) the stability of NMR in plasma, saliva, and blood in various storage conditions, (ii) the relationship between NMRs derived from blood, plasma, saliva, and urine, and (iii) the reproducibility of plasma NMR in ad libitum cigarette smokers.
METHODS: We analyzed data from four clinical studies. In studies 1 and 2, we assessed NMR stability in saliva and plasma samples at room temperature (~22°C) over 14 days and in blood at 4°C for up to 72 hours. In studies 2 and 3, we used Bland-Altman analysis to assess agreement between blood, plasma, saliva, and urine NMRs. In study 4, plasma NMR was measured on six occasions over 44 weeks in 43 ad libitum smokers.
RESULTS: Reliability coefficients for stability tests of NMR in plasma and saliva at room temperature were 0.97 and 0.98, respectively, and 0.92 for blood at 4°C. Blood NMR agreed consistently with saliva and plasma NMRs but showed more variability in relation to urine NMR. The reliability coefficient for repeated plasma NMR measurements in smokers was 0.85.
CONCLUSION: The NMR is stable in blood, plasma, and saliva at the conditions tested. Blood, plasma, and saliva NMRs are similar whereas urine NMR is a good proxy for these NMR measures. Plasma NMR was reproducible over time in smokers. IMPACT: One measurement may reliably estimate a smoker's NMR for use as an estimate of the rate of nicotine metabolism. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552800      PMCID: PMC3392523          DOI: 10.1158/1055-9965.EPI-12-0236

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  29 in total

1.  Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity.

Authors:  Delia Dempsey; Piotr Tutka; Peyton Jacob; Faith Allen; Kerri Schoedel; Rachel F Tyndale; Neal L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

2.  Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk.

Authors:  Catherine A Wassenaar; Qiong Dong; Qingyi Wei; Christopher I Amos; Margaret R Spitz; Rachel F Tyndale
Journal:  J Natl Cancer Inst       Date:  2011-07-11       Impact factor: 13.506

3.  Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking.

Authors:  N L Benowitz; P Jacob
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

4.  Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.

Authors:  Andrew A Strasser; Neal L Benowitz; Angela G Pinto; Kathy Z Tang; Stephen S Hecht; Steve G Carmella; Rachel F Tyndale; Caryn E Lerman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-01-06       Impact factor: 4.254

Review 5.  Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence.

Authors:  Oliver West; Peter Hajek; Hayden McRobbie
Journal:  Psychopharmacology (Berl)       Date:  2011-05-20       Impact factor: 4.530

6.  Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.

Authors:  Neal L Benowitz; Katherine M Dains; Sharon M Hall; Susan Stewart; Margaret Wilson; Delia Dempsey; Peyton Jacob
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-02-21       Impact factor: 4.254

7.  New CYP2A6 gene deletion and conversion variants in a population of Black African descent.

Authors:  Jill C Mwenifumbo; Qian Zhou; Neal L Benowitz; Edward M Sellers; Rachel F Tyndale
Journal:  Pharmacogenomics       Date:  2010-02       Impact factor: 2.533

8.  Nicotine metabolite ratio as a predictor of cigarette consumption.

Authors:  Neal L Benowitz; Ovide F Pomerleau; Cynthia S Pomerleau; Peyton Jacob
Journal:  Nicotine Tob Res       Date:  2003-10       Impact factor: 4.244

9.  The nicotine dependence syndrome scale: a multidimensional measure of nicotine dependence.

Authors:  Saul Shiffman; Andrew Waters; Mary Hickcox
Journal:  Nicotine Tob Res       Date:  2004-04       Impact factor: 4.244

Review 10.  Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction.

Authors:  N L Benowitz
Journal:  Clin Pharmacol Ther       Date:  2008-02-27       Impact factor: 6.875

View more
  65 in total

Review 1.  Alternative Sampling Strategies for Cytochrome P450 Phenotyping.

Authors:  Pieter M M De Kesel; Willy E Lambert; Christophe P Stove
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 2.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

3.  A Comparison of Direct and Indirect Analytical Approaches to Measuring Total Nicotine Equivalents in Urine.

Authors:  Taraneh Taghavi; Maria Novalen; Caryn Lerman; Tony P George; Rachel F Tyndale
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-31       Impact factor: 4.254

4.  The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race.

Authors:  Robert A Schnoll; Tony P George; Larry Hawk; Paul Cinciripini; Paul Wileyto; Rachel F Tyndale
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

5.  Evaluation of a weighted genetic risk score for the prediction of biomarkers of CYP2A6 activity.

Authors:  Ahmed El-Boraie; Taraneh Taghavi; Meghan J Chenoweth; Koya Fukunaga; Taisei Mushiroda; Michiaki Kubo; Caryn Lerman; Nicole L Nollen; Neal L Benowitz; Rachel F Tyndale
Journal:  Addict Biol       Date:  2019-02-27       Impact factor: 4.280

Review 6.  Biomarkers of exposure to new and emerging tobacco delivery products.

Authors:  Suzaynn F Schick; Benjamin C Blount; Peyton Jacob; Najat A Saliba; John T Bernert; Ahmad El Hellani; Peter Jatlow; R Steven Pappas; Lanqing Wang; Jonathan Foulds; Arunava Ghosh; Stephen S Hecht; John C Gomez; Jessica R Martin; Clementina Mesaros; Sanjay Srivastava; Gideon St Helen; Robert Tarran; Pawel K Lorkiewicz; Ian A Blair; Heather L Kimmel; Claire M Doerschuk; Neal L Benowitz; Aruni Bhatnagar
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-05-18       Impact factor: 5.464

7.  The Nicotine Metabolite Ratio is Associated With Early Smoking Abstinence Even After Controlling for Factors That Influence the Nicotine Metabolite Ratio.

Authors:  Meghan J Chenoweth; Robert A Schnoll; Maria Novalen; Larry W Hawk; Tony P George; Paul M Cinciripini; Caryn Lerman; Rachel F Tyndale
Journal:  Nicotine Tob Res       Date:  2015-06-11       Impact factor: 4.244

8.  Measures and predictors of varenicline adherence in the treatment of nicotine dependence.

Authors:  Annie R Peng; Mark Morales; E Paul Wileyto; Larry W Hawk; Paul Cinciripini; Tony P George; Neal L Benowitz; Nicole L Nollen; Caryn Lerman; Rachel F Tyndale; Robert Schnoll
Journal:  Addict Behav       Date:  2017-07-12       Impact factor: 3.913

Review 9.  Biomarkers for smoking cessation.

Authors:  K J Bough; C Lerman; J E Rose; F J McClernon; P J Kenny; R F Tyndale; S P David; E A Stein; G R Uhl; D V Conti; C Green; S Amur
Journal:  Clin Pharmacol Ther       Date:  2013-03-18       Impact factor: 6.875

10.  Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.

Authors:  Julie-Anne Tanner; Jeffrey A Henderson; Dedra Buchwald; Barbara V Howard; Patricia Nez Henderson; Rachel F Tyndale
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.